3,798 Shares in Glaukos Co. (NYSE:GKOS) Bought by Bokf Na

Bokf Na acquired a new stake in Glaukos Co. (NYSE:GKOS) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 3,798 shares of the medical instruments supplier’s stock, valued at approximately $595,000.

Other large investors also recently modified their holdings of the company. IFP Advisors Inc bought a new position in shares of Glaukos during the fourth quarter worth about $43,000. Asset Planning Inc bought a new position in Glaukos during the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management acquired a new position in shares of Glaukos in the 4th quarter worth approximately $125,000. SBI Securities Co. Ltd. bought a new stake in shares of Glaukos in the 4th quarter valued at approximately $153,000. Finally, Smartleaf Asset Management LLC raised its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after acquiring an additional 807 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on GKOS shares. Wells Fargo & Company downgraded shares of Glaukos from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $160.00 to $86.00 in a report on Thursday, May 1st. Stephens lowered their price objective on shares of Glaukos from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, May 2nd. Truist Financial reissued a “buy” rating and issued a $135.00 target price (down previously from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Morgan Stanley decreased their target price on Glaukos from $110.00 to $72.00 and set an “underweight” rating for the company in a research note on Tuesday. Finally, Needham & Company LLC cut their price target on Glaukos from $176.00 to $115.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $134.67.

Insider Activity

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Glaukos Trading Down 0.7 %

Shares of GKOS stock opened at $89.94 on Friday. Glaukos Co. has a 1 year low of $77.10 and a 1 year high of $163.71. The firm has a market capitalization of $5.14 billion, a PE ratio of -31.34 and a beta of 0.83. The stock has a fifty day moving average of $94.87 and a two-hundred day moving average of $127.35. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company’s quarterly revenue was up 24.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.70) earnings per share. As a group, research analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.